A growing interest in cognitive dysfunction in MDD has improved our ability to assess and
treat MDD. Future research will be strengthened by the use of consistent terminology …

A thorough understanding of the cognitive effects of antidepressant medications is essential
given their frequency of use. This meta-analysis was conducted to investigate whether …

This multicenter, randomized, double-blind, placebo-controlled, active-referenced
(duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of …

Background: Management of cognitive deficits in Major Depressive Disorder (MDD) remains
an important unmet need. This meta-analysis evaluated the effects of vortioxetine on …

Background Major depressive disorder is a common condition that often includes cognitive
dysfunction. A systematic literature review of studies and a network meta-analysis were …

Evidence suggesting that central nervous system γ-aminobutyric acid (GABA)
concentrations are reduced in patients with major depressive disorder (MDD) has been …

Depression is a risk factor for the development of Alzheimer's disease (AD), and the
presence of depressive symptoms significantly increases the conversion of mild cognitive …

It has been known for several decades that serotonergic neurotransmission is a key
regulator of cognitive function, mood, and sleep. Yet with the relatively recent discoveries of …

Introduction: Vortioxetine is a structurally novel medication that has recently been approved
for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake …

Second-generation antidepressants (SGADs) often cause neurological side effects (SEs).
This meta-analysis seeks to quantify the short-term rates of neurological SEs related to …